Radiopharm Theranostics ups stake in US cancer-fighting venture
Radiopharm Theranostics (ASX: RAD) has boosted its stake in a United States-based joint venture (JV) with the University of Texas MD...
top of page
Search
James Pearson
- Aug 20
US medical guru jumps into Radiopharm Theranostics cancer fight
Radiopharm Theranostics (ASX: RAD) has secured the services of United States-based Dr Dimitris Voliotis as its new chief medical officer...
James Pearson
- Aug 5
Radiopharm Theranostics banks US$2m in sales to American medical giant
Radiopharm Theranostics (ASX: RAD) has banked US$2 million (AU$3.1 million) from American medical giant Lantheus for the sale of two...
James Pearson
- Jul 23
Radiopharm gets crucial nod for brain cancer imaging trial
Radiopharm Theranostics (ASX: RAD) has been given the nod of approval by the United States Food and Drug Authority to use its brain...
James Pearson
- Jul 10
Radiopharm Theranostics unveils landmark human lung cancer trial
Radiopharm Theranostics (ASX: RAD) has kicked off the first phase of clinical trials testing its “RAD 204” treatment aimed at beating the...
Bart Bogacz
- Jun 25
Radiopharm Theranostics soars on $70m funding for cancer treatment
Radiopharm Theranostics’ (ASX: RAD) stock rocketed up more than 35 per cent this morning after the cancer-fighting firm secured...
Michael Philipps
- Jun 20
Radiopharm Theranostics set for $18 million boost in Lantheus deal
Radiopharm Theranostics (ASX: RAD) looks set to fill its coffers with a healthy $18 million following a strategic equity investment and...
Doug Bright
- Mar 18
Radiopharm eyes kidney protection in cancer radiotherapy
The potential for one of Radiopharm Theranostics’ (ASX: RAD) treatments to fight cancer while protecting a patient’s kidneys from...
Doug Bright
- Mar 1
Terbium emerging as cancer-fighting key for Radiopharm
Radiopharm Theranostics says a new six-patient study shows its terbium-based treatment has superior potential to tackle prostate cancer...
Michael Philipps
- Feb 29
First pancreatic cancer patient dosed in Radiopharm study
Radiopharm Theranostics says it has dosed its first pancreatic cancer patient in the initial phase of a study aimed at providing doctors...
Doug Bright
- Feb 6
Radiopharm strikes new blow in fighting aggressive tumours
An immune system protein being developed by Radiopharm Theranostics has for the first time been shown to have the potential to detect and...
Doug Bright
- Dec 27, 2023
Radiopharm expands lung cancer trials sites to Perth
Radiopharm Theranostics is poised to open a second site for conducting human trials of its RAD 204 treatment for advanced non-small cell...
Doug Bright
- Dec 22, 2023
Radiopharm set for “game-changing” lung cancer trial
Radiopharm Theranostics has stepped closer to kicking off what it says could be a “game-changing” trial for patients with non-small cell...
Doug Bright
- Nov 21, 2023
Tax rebate to help Radiopharm diagnose, treat cancers
A research and development (R&D) tax rebate of nearly $5 million from the Australian Government will boost Radiopharm Theranostics’...
Doug Bright
- Oct 17, 2023
Radiopharm trials to lift pancreatic cancer hopes
Pancreatic cancer patients have been delivered fresh hope following the United States Food and Drug Administration’s decision to clear...
Doug Bright
- Oct 9, 2023
Radiopharm Theranostics green-lighted for radioactive lung cancer trial
The Human Research Ethics Committee (HREC) has given Radiopharm Theranostics its stamp of approval to begin first-in-human phase-one dose...
Steve Butler
- Aug 24, 2023
Radiopharm inks new deal in fight against prostate cancer
Radiopharm Theranostics has negotiated an expanded agreement with TerThera for the supply of the terbium-161 (Tb-161) isotope to continue...
Michael Philipps
- May 29, 2023
Radiopharm gets big boost for brain cancer trials bid
A positive meeting with the United States Food and Drug Administration (USFDA) has boosted Radiopharm Theranostics’ approval prospects...
Michael Philipps
- May 9, 2023
Radiopharm Theranostics secures US approval for second cancer treatment
A pancreatic cancer treatment developed by ASX-listed Radiopharm Theranostics has been granted crucial orphan drug designation by the...
bottom of page